RBT at the Sirius.Biotech summit

list

RBT (BioTechnologies Development), part of the Artgen Biotech group (MOEX: ABIO), has become an official partner of the Sirius.Biotech drug development summit.

Sirius. Biotech was held at the Sirius University of Science and Technology on May 15-17. It was attended by scientists, experts, specialists from the country's leading pharmaceutical companies and representatives of research centers and institutes. The summit set a record with regard to the number of delegates - more than 800 people - one and a half times more than in 2023.

Experts spoke about the main technological platforms for the development and production of drugs and discussed the latest trends in the biotechnology industry. The key topics of the summit were: gene therapy, AI in drug development, mRNA vaccines, approaches to overcoming antibiotic resistance and regulatory aspects of drug development.

Igor Krasilnikov, RBT Director, moderated a special session "Recombinant vaccines" and also made a presentation on the topic: "Creation of safe vaccines based on the Betusfera corpuscular adjuvant".

Last year, RBT and Sirius University entered into an agreement to develop technology for producing recombinant influenza antigens to create universal and more effective influenza vaccines. The research will last 2 years at the Research Center for Translational Medicine at Sirius University in one of the largest laboratory complexes in our country in the field of life sciences.

The Sirius University of Science and Technology was founded in 2019. The university implements projects in the field of genomics, immunobiology, biotechnology, neurobiology, gene therapy, plant genome editing, robotics, and clinical psychology. Under the leadership of the country's leading scientists, 17 scientific and educational units have been opened, jointly implementing interdisciplinary educational programs and research projects aimed at improving the quality of life of the population.